Redmile Group LLC grew its holdings in AnaptysBio Inc (NASDAQ:ANAB) by 0.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 612,558 shares of the biotechnology company’s stock after buying an additional 2,900 shares during the quarter. Redmile Group LLC owned approximately 2.26% of AnaptysBio worth $21,433,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Amundi Pioneer Asset Management Inc. bought a new position in shares of AnaptysBio in the 1st quarter worth approximately $110,000. Whittier Trust Co. purchased a new position in shares of AnaptysBio during the 2nd quarter worth $213,000. Quantitative Systematic Strategies LLC bought a new stake in shares of AnaptysBio during the 2nd quarter valued at $258,000. Los Angeles Capital Management & Equity Research Inc. grew its position in shares of AnaptysBio by 15.1% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 12,470 shares of the biotechnology company’s stock valued at $704,000 after acquiring an additional 1,635 shares during the period. Finally, Janney Montgomery Scott LLC grew its position in shares of AnaptysBio by 6.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,226 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 251 shares during the period.
Several equities analysts recently weighed in on ANAB shares. Wedbush downgraded AnaptysBio from an “outperform” rating to a “neutral” rating in a research report on Friday, November 8th. BidaskClub raised shares of AnaptysBio from a “strong sell” rating to a “sell” rating in a research note on Friday, October 18th. JPMorgan Chase & Co. downgraded shares of AnaptysBio from an “overweight” rating to an “underweight” rating and reduced their target price for the stock from $109.00 to $17.00 in a report on Friday, November 8th. ValuEngine upgraded AnaptysBio from a “hold” rating to a “buy” rating in a research report on Friday, August 16th. Finally, Jefferies Financial Group cut shares of AnaptysBio from a “buy” rating to a “hold” rating and set a $12.00 price objective on the stock. in a research report on Friday, November 8th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $75.11.
Shares of NASDAQ:ANAB traded down $0.21 during trading on Friday, reaching $14.02. The stock had a trading volume of 653,084 shares, compared to its average volume of 441,612. The firm’s 50-day simple moving average is $23.95 and its 200 day simple moving average is $45.36. AnaptysBio Inc has a one year low of $10.00 and a one year high of $83.10. The company has a market capitalization of $391.80 million, a P/E ratio of -5.61 and a beta of 1.12.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Friday, November 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.06). During the same period last year, the business earned ($0.66) earnings per share. As a group, analysts forecast that AnaptysBio Inc will post -4.01 earnings per share for the current year.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company’s products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Receive News & Ratings for AnaptysBio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AnaptysBio and related companies with MarketBeat.com’s FREE daily email newsletter.